Market Research Logo

Generics in India

Generics in India

Summary

Generics in India industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the India generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The market value is evaluated at ex-factory prices.

Market volume is quantified here as the percentage of the total ethical pharmaceutical market volume in a country or region which is accounted for by generic drugs. It is therefore a generics penetration rate measure, not an absolute measure of market volume.

Regional volumes are calculated as weighted averages of countries which make up the region in question where volume data exists.

Please note that any volumes of 1 (one) or 100% are due to rounding as MarketLine does not believe that generics will ever fully represent 100% of the medicinal market in any country or region.

All currency conversions were calculated at constant average annual 2016 exchange rates.

The Indian generics market had total revenues of $12,654.0m in 2016, representing a compound annual growth rate (CAGR) of 11.3% between 2012 and 2016.

Market consumption volume increased with a CAGR of 0.7% between 2012 and 2016, to reach a total of 95.2% of total pharma volume in 2016.

Growth is expected to decelerate but generics companies will benefit indirectly from increased public health education led by large pharmaceutical companies.

Scope

  • Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in India
  • Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in India
  • Leading company profiles reveal details of key generics market players’ global operations and financial performance
  • Add weight to presentations and pitches by understanding the future growth prospects of the India generics market with five year forecasts by both value and volume
Reasons to buy
  • What was the size of the India generics market by value in 2016?
  • What will be the size of the India generics market in 2021?
  • What factors are affecting the strength of competition in the India generics market?
  • How has the market performed over the last five years?
  • How large is India’s generics market in relation to its regional counterparts?


Executive Summary
Market value
Market value forecast
Market volume
Market volume forecast
Geography segmentation
Market rivalry
Market Overview
Market definition
Market analysis
Market Data
Market value
Market volume
Market Segmentation
Geography segmentation
Market Outlook
Market value forecast
Market volume forecast
Five Forces Analysis
Summary
Buyer power
Supplier power
New entrants
Threat of substitutes
Degree of rivalry
Leading Companies
Aurobindo Pharma Limited
Cipla Limited
Lupin Ltd
Sun Pharmaceutical Industries Ltd
Macroeconomic Indicators
Country data
Methodology
Industry associations
Related MarketLine research
Appendix
About MarketLine
List of Tables
Table 1: India generics market value: $ million, 2012-16
Table 2: India generics market volume: % of total pharma volume, 2012-16
Table 3: India generics market geography segmentation: $ million, 2016
Table 4: India generics market value forecast: $ million, 2016-21
Table 5: India generics market volume forecast: % of total pharma volume, 2016-21
Table 6: Aurobindo Pharma Limited: key facts
Table 7: Aurobindo Pharma Limited: key financials ($)
Table 8: Aurobindo Pharma Limited: key financials (A$)
Table 9: Aurobindo Pharma Limited: key financial ratios
Table 10: Cipla Limited: key facts
Table 11: Cipla Limited: key financials ($)
Table 12: Cipla Limited: key financials (Rs.)
Table 13: Cipla Limited: key financial ratios
Table 14: Lupin Ltd: key facts
Table 15: Lupin Ltd: key financials ($)
Table 16: Lupin Ltd: key financials (Rs.)
Table 17: Lupin Ltd: key financial ratios
Table 18: Sun Pharmaceutical Industries Ltd: key facts
Table 19: Sun Pharmaceutical Industries Ltd: key financials ($)
Table 20: Sun Pharmaceutical Industries Ltd: key financials (Rs.)
Table 21: Sun Pharmaceutical Industries Ltd: key financial ratios
Table 22: India size of population (million), 2012-16
Table 23: India gdp (constant 2005 prices, $ billion), 2012-16
Table 24: India gdp (current prices, $ billion), 2012-16
Table 25: India inflation, 2012-16
Table 26: India consumer price index (absolute), 2012-16
Table 27: India exchange rate, 2012-16
List of Figures
Figure 1: India generics market value: $ million, 2012-16
Figure 2: India generics market volume: % of total pharma volume, 2012-16
Figure 3: India generics market geography segmentation: % share, by value, 2016
Figure 4: India generics market value forecast: $ million, 2016-21
Figure 5: India generics market volume forecast: % of total pharma volume, 2016-21
Figure 6: Forces driving competition in the generics market in India, 2016
Figure 7: Drivers of buyer power in the generics market in India, 2016
Figure 8: Drivers of supplier power in the generics market in India, 2016
Figure 9: Factors influencing the likelihood of new entrants in the generics market in India, 2016
Figure 10: Factors influencing the threat of substitutes in the generics market in India, 2016
Figure 11: Drivers of degree of rivalry in the generics market in India, 2016
Figure 12: Aurobindo Pharma Limited: revenues & profitability
Figure 13: Aurobindo Pharma Limited: assets & liabilities
Figure 14: Cipla Limited: revenues & profitability
Figure 15: Cipla Limited: assets & liabilities
Figure 16: Lupin Ltd: revenues & profitability
Figure 17: Lupin Ltd: assets & liabilities
Figure 18: Sun Pharmaceutical Industries Ltd: revenues & profitability
Figure 19: Sun Pharmaceutical Industries Ltd: assets & liabilities

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report